Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

222 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Neoadjuvant chemotherapy and radiotherapy for locally advanced breast cancer: Safety and efficacy of reverse sequence compared to standard technique?
Maire M, Debled M, Petit A, Fournier M, Macgrogan G, Quenel-Thueux N, Charitansky H, Mathoulin-Pelissier S, Bonnefoi H, Tunon de Lara C. Maire M, et al. Among authors: macgrogan g. Eur J Surg Oncol. 2022 Aug;48(8):1699-1705. doi: 10.1016/j.ejso.2022.04.022. Epub 2022 Apr 29. Eur J Surg Oncol. 2022. PMID: 35523623
[Large core of nonpalpable breast lesions].
MacGrogan G, Henriques C, De Mascarel I, Soubeyran I, Molimard J, Barreau B, Tunon De Lara C, Bussieres E, Dilhuydy MH. MacGrogan G, et al. Arch Anat Cytol Pathol. 1998;46(4):241-6. Arch Anat Cytol Pathol. 1998. PMID: 9754385 French.
Analysis of 676 cases of ductal carcinoma in situ of the breast from 1971 to 1995: diagnosis and treatment--the experience of one institute.
Tunon-de-Lara C, de-Mascarel I, Mac-Grogan G, Stöckle E, Jourdain O, Acharian V, Guegan C, Faucher A, Bussieres E, Trojani M, Bonichon F, Barreau B, Dilhuydy MH, Dilhuydy JM, Mauriac L, Durand M, Avril A. Tunon-de-Lara C, et al. Am J Clin Oncol. 2001 Dec;24(6):531-6. doi: 10.1097/00000421-200112000-00001. Am J Clin Oncol. 2001. PMID: 11801749
Locally advanced/inflammatory breast cancers treated with intensive epirubicin-based neoadjuvant chemotherapy: are there molecular markers in the primary tumour that predict for 5-year clinical outcome?
Bonnefoi H, Diebold-Berger S, Therasse P, Hamilton A, van de Vijver M, MacGrogan G, Shepherd L, Amaral N, Duval C, Drijkoningen R, Larsimont D, Piccart M. Bonnefoi H, et al. Among authors: macgrogan g. Ann Oncol. 2003 Mar;14(3):406-13. doi: 10.1093/annonc/mdg108. Ann Oncol. 2003. PMID: 12598346 Free article. Clinical Trial.
222 results